trending Market Intelligence /marketintelligence/en/news-insights/trending/l5j9yhbrozwo7zel7_uufg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Proteostasis plans common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Proteostasis plans common stock offering

Proteostasis Therapeutics Inc. plans to sell 9 million common shares in an underwritten public offering

The company plans to grant the underwriters an option to buy up to an additional 15%, or 1,350,000 common shares, in the public offering.

Leerink Partners and RBC Capital Markets are acting as joint book-running managers, and H.C. Wainwright & Co. is acting as lead manager for the offering.